Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 11
2004 7
2005 7
2006 9
2007 11
2008 9
2009 10
2010 7
2011 6
2012 13
2013 6
2014 12
2015 7
2016 11
2017 17
2018 9
2019 9
2020 9
2021 10
2022 13
2023 3
2024 8
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.
Sciortino C, Nichetti F, Bergamo F, Palermo F, Tamberi S, Vivaldi C, Ongaro E, Arcangeli G, Marchesi S, Giommoni E, Cella CA, Pircher C, Chiaramonte A, Bencardino K, Sottotetti E, Martinetti A, Rapposelli IG, Corallo S, Di Donato S, Murialdo R, Delliponti L, Salvatore L, Bozzarelli S, Dell'Aquila E, Miceli R, Carnaghi C, Tomasello G, Rivizzigno P, Bonomi M, Mannavola F, Forti L, Garajovà I, Attademo L, Galassi B, Chiari R, Leone F, Garattini SK, Tamburini E, Pietrantonio F, Niger M. Sciortino C, et al. Among authors: garattini sk. Dig Liver Dis. 2025 Nov 28:S1590-8658(25)01206-X. doi: 10.1016/j.dld.2025.11.007. Online ahead of print. Dig Liver Dis. 2025. PMID: 41318310
Do Not Let the Guard Down on Preventable Behavioral Risk Factors.
Stival C, Odone A, Lugo A, van den Brandt PA, Garattini S, Gallus S. Stival C, et al. Among authors: garattini s. J Epidemiol. 2025 Nov 5;35(11):465-471. doi: 10.2188/jea.JE20250037. Epub 2025 Sep 30. J Epidemiol. 2025. PMID: 40545344 Free PMC article.
CardioPulmonary resuscitation with Argon (CPAr): A protocol for a randomised controlled multicentre clinical trial.
Ristagno G, Staszewsky L, Merigo G, Magliocca A, Cucino A, Meessen J, Fumagalli F, Pozzi M, Galazzi A, Sandroni C, Meneguzzi M, Marangone A, Robba C, Roman-Pognuz E, Salati G, Picetti E, Novelli D, Bellani G, Panigada M, Wik L, Garattini S, Foti G, Antonelli M, Zanier E, Grasselli G, Latini R; CPAr Study group. Ristagno G, et al. Among authors: garattini s. Resusc Plus. 2025 Sep 10;26:101096. doi: 10.1016/j.resplu.2025.101096. eCollection 2025 Nov. Resusc Plus. 2025. PMID: 41079544 Free PMC article.
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti O, De Vita F, Bittoni A, Chini C, Spallanzani A, Nappo F, Bethaz V, Strippoli A, Latiano T, Cardellino GG, Giuliani F, Morano F, Niger M, Raimondi A, Prisciandaro M, Pircher CC, Sciortino C, Marchesi S, Garattini SK, Airò G, Miceli R, Di Bartolomeo M, Pietrantonio F. Randon G, et al. Among authors: garattini sk. Lancet Oncol. 2024 Dec;25(12):1539-1550. doi: 10.1016/S1470-2045(24)00580-1. Epub 2024 Nov 15. Lancet Oncol. 2024. PMID: 39557058 Clinical Trial.
Clinical Application of Radiomics in Oncology: Where Do We Stand?
Pascuzzo R, Garattini SK, Doniselli FM. Pascuzzo R, et al. Among authors: garattini sk. J Magn Reson Imaging. 2024 Dec;60(6):2745-2746. doi: 10.1002/jmri.29340. Epub 2024 Mar 13. J Magn Reson Imaging. 2024. PMID: 38477019 Free article. No abstract available.
Paving the way towards medicines for women and men.
Banzi R, Garattini S. Banzi R, et al. Among authors: garattini s. Eur J Clin Pharmacol. 2024 Aug;80(8):1255-1256. doi: 10.1007/s00228-024-03683-9. Epub 2024 Apr 9. Eur J Clin Pharmacol. 2024. PMID: 38592471 No abstract available.
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A. Rimini M, et al. Among authors: garattini sk. Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1. Target Oncol. 2024. PMID: 38691295
194 results